Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial

被引：2
|
作者：
Rosellini, Matteo [1 ,2 ]
Tassinari, Elisa [1 ,2 ]
Marchetti, Andrea [1 ,2 ]
Mollica, Veronica [1 ,2 ]
Massari, Francesco [1 ,2 ,3 ]
机构：
[1] Univ Bologna, Med Oncol Unit, IRCCS Azienda Osped, Bologna, Italy
[2] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy
[3] Univ Bologna, Med Oncol Dept, IRCCS Azienda Osped, Via Albertoni 15, Bologna, Italy
来源：
EUROPEAN UROLOGY | 2024年 / 85卷 / 01期
关键词：
D O I：
10.1016/j.eururo.2023.09.011
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：97 / 98
页数：2
相关论文
共 50 条
  • [31] A phase 3, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Azad, Arun
    Agarwal, Neeraj
    Carles, Joan
    Chowdhury, Simon
    McGregor, Bradley
    Merseburger, Axel
    Oudard, Stephane
    Saad, Fred
    Soares, Andrey
    Kerloeguen, Yannick
    Benzaghou, Fawzi
    Panneerselvam, Ashok
    Mohamed, Nehal
    Wang, Fong
    Pal, Sumanta
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 201 - 201
  • [32] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial
    Qin, Shukui
    Chen, Minshan
    Cheng, Ann-Lii
    Kaseb, Ahmed
    Kudo, Masatoshi
    Lee, Han Chu
    Yopp, Adam C.
    Zhou, Jian
    Wang, Lu
    Wen, Xiaoyu
    Heo, Jeong
    Tak, Won Young
    Nakamura, Shinichiro
    Numata, Kazushi
    Uguen, Thomas
    Hsiehchen, David
    Cha, Edward
    Hack, Stephen P.
    Lian, Qinshu
    Ma, Ning
    Spahn, Jessica H.
    Wang, Yulei
    Wu, Chun
    Chow, Pierce K. H.
    LANCET, 2023, 402 (10415): : 1835 - 1847
  • [33] Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
    Antoniotti, Carlotta
    Rossini, Daniele
    Pietrantonio, Filippo
    Catteau, Aurelie
    Salvatore, Lisa
    Lonardi, Sara
    Boquet, Isabelle
    Tamberi, Stefano
    Marmorino, Federica
    Moretto, Roberto
    Ambrosini, Margherita
    Tamburini, Emiliano
    Tortora, Giampaolo
    Passardi, Alessandro
    Bergamo, Francesca
    Kassambara, Alboukadel
    Sbarrato, Thomas
    Morano, Federica
    Ritorto, Giuliana
    Borelli, Beatrice
    Boccaccino, Alessandra
    Conca, Veronica
    Giordano, Mirella
    Ugolini, Clara
    Fieschi, Jacques
    Papadopulos, Alexia
    Massoue, Clementine
    Aprile, Giuseppe
    Antonuzzo, Lorenzo
    Gelsomino, Fabio
    Martinelli, Erika
    Pella, Nicoletta
    Masi, Gianluca
    Fontanini, Gabriella
    Boni, Luca
    Galon, Jerome
    Cremolini, Chiara
    LANCET ONCOLOGY, 2022, 23 (07): : 876 - 887
  • [34] Open-label phase II trial of everolimus monotherapy in treatment-naive patients with advanced papillary renal cell carcinoma
    Caglio, S.
    Slimane, K.
    May, C.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
    Galle, Peter R.
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Zhu, Andrew X.
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Mulla, Sohail
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Ding, Beiying
    Liu, Juan
    Huang, Chen
    Lim, Ho Yeong
    Cheng, Ann-Lii
    Ducreux, Michel
    LANCET ONCOLOGY, 2021, 22 (07): : 991 - 1001
  • [36] Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
    Neal, Joel W.
    Dahlberg, Suzanne E.
    Wakelee, Heather A.
    Aisner, Seena C.
    Bowden, Michaela
    Huang, Ying
    Carbone, David P.
    Gerstner, Gregory J.
    Lerner, Rachel E.
    Rubin, Jerome L.
    Owonikoko, Taofeek K.
    Stella, Philip J.
    Steen, Preston D.
    Khalid, Ahmed Ali
    Ramalingam, Suresh S.
    LANCET ONCOLOGY, 2016, 17 (12): : 1661 - 1671
  • [37] A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
    Procopio, Giuseppe
    Claps, Melanie
    Pircher, Chiara
    Porcu, Luca
    Sepe, Pierangela
    Guadalupi, Valentina
    De Giorgi, Ugo
    Bimbatti, Davide
    Nole, Franco
    Carrozza, Francesco
    Buti, Sebastiano
    Iacovelli, Roberto
    Ciccarese, Chiara
    Masini, Cristina
    Baldessari, Cinzia
    Doni, Laura
    Cusmai, Antonio
    Gernone, Angela
    Scagliarini, Sarah
    Pignata, Sandro
    de Braud, Filippo
    Verzoni, Elena
    TUMORI JOURNAL, 2023, 109 (01): : 129 - 137
  • [38] Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial
    Marandino, L.
    Raggi, D.
    Calareso, G.
    Alessi, A.
    Colecchia, M.
    Martini, A.
    Briganti, A.
    Montorsi, F.
    Madison, R.
    Ross, J. S.
    Necchi, A.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (05) : 457 - 465
  • [39] Phase 2 trial for sequential treatment of high dose cabozantinib (CABO) or CABO plus nivolumab (NIVO) on/after progression on CABO monotherapy in advanced renal cell carcinoma (RCC): Seq-Cabo
    Qin, Qian
    Brugarolas, James
    Hammers, Hans J.
    Arafat, Waddah
    Courtney, Kevin Dale
    Wang, Jue
    Jiang, Changchuan
    Zhang, Song
    Cowey, Charles Lance
    Hutson, Thomas E.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
    Westerman, Mary E.
    Wood, Christopher G.
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (16)
12345